Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial
Frontiers in Nutrition · 27.03.2023 · 10
DOI: 10.3389/fnut.2023.1104169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 27.03.2023. Verfasst von Marzieh Heidari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tabriz University of Medical Sciences.
Abstract (Originalsprache)
Background
Atherosclerosis can develop as a result of an increase in oxidative stress and concurrently rising levels of inflammation. Astaxanthin (AX), a red fat-soluble pigment classified as a xanthophyll, may be able to prevent the vascular damage induced by free radicals and the activation of inflammatory signaling pathways. The objective of the current study is to assess the effects of AX supplementation on cardiometabolic risk factors in individuals with coronary artery disease (CAD).
Methods
This randomized double-blind placebo-controlled clinical trial was conducted among 50 CAD patients. Participants were randomly allocated into two groups to intake either AX supplements (12 mg/day) or placebo for 8 weeks. Lipid profile, glycemic parameters, anthropometric indices, body composition, Siruin1 and TNF-α levels were measured at baseline and after 8 weeks.
Results
Body composition, glycemic indices, serum levels of TNF-α, Sirtuin1 did not differ substantially between the AX and placebo groups ( p > 0.05). The data of AX group showed significant reduction in total cholesterol (−14.95 ± 33.57 mg/dl, p < 0.05) and LDL-C (−14.64 ± 28.27 mg/dl, p < 0.05). However, TG and HDL-C levels could not be affected through AX supplementation.
Conclusion
Our results suggest that AX supplementation play a beneficial role in reducing some components of lipid profile levels. However, further clinical investigations in CAD patients are required to obtain more conclusive findings. Clinical trial registration www.Irct.ir ., identifier IRCT20201227049857N1.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.
- Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Förderung
- Tabriz University of Medical Sciences
Zitieren
APA
Heidari, M., Chaboksafar, M., Alizadeh, M., Sohrabi, B., & Kheirouri, S. (2023). Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial. Frontiers in Nutrition, 10. https://doi.org/10.3389/fnut.2023.1104169
Vancouver
Heidari M, Chaboksafar M, Alizadeh M, Sohrabi B, Kheirouri S. Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial. Frontiers in Nutrition. 2023;10. doi:10.3389/fnut.2023.1104169
BibTeX
@article{Heidari2023,
author = {Heidari, Marzieh and Chaboksafar, Maryam and Alizadeh, Mohammad and Sohrabi, Bahram and Kheirouri, Sorayya},
title = {Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial},
journal = {Frontiers in Nutrition},
year = {2023},
volume = {10},
doi = {10.3389/fnut.2023.1104169}
}
EUVIMED